ES2151897T3 - Benzoxazinonas como inhibidores de la transcriptasa inversa de vih. - Google Patents

Benzoxazinonas como inhibidores de la transcriptasa inversa de vih.

Info

Publication number
ES2151897T3
ES2151897T3 ES93306114T ES93306114T ES2151897T3 ES 2151897 T3 ES2151897 T3 ES 2151897T3 ES 93306114 T ES93306114 T ES 93306114T ES 93306114 T ES93306114 T ES 93306114T ES 2151897 T3 ES2151897 T3 ES 2151897T3
Authority
ES
Spain
Prior art keywords
benzoxazinonas
inhibitors
reverse transcript
hiv reverse
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93306114T
Other languages
English (en)
Inventor
Steven D Young
Lekhanh O Tran
Susan F Britcher
William C Lumma Jr
Linda S Payne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26733517&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2151897(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2151897T3 publication Critical patent/ES2151897T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE PRESENTAN CIERTAS BENZOXACINONAS DE LA FORMULA I EN LA QUE X ES HALO, X1 ES TRIHALOMETIL O PENTAHALOMETIL; Z ES O; LOS COMPUESTOS SON UTILES EN LA INHIBICION DE LA TRANSCRIPTASA INVERSA DEL HIV (INCLUYENDO SUS VARIEDADES RESISTENTES), EN LA PREVENCION O EL TRATAMIENTO DE INFECCIONES POR HIV Y EN EL TRATAMIENTO DEL SIDA, TANTO COMO COMPUESTOS, SALES FARMACOLOGICAMENTE ACEPTABLES, INGREDIENTES PARA COMPOSICIONES FARMACEUTICAS, SOLAS O EN COMBINACION CON OTROS ANTIVIRALES, INMUNOMODULADORES, ANTIBIOTICOS O VACUNAS. TAMBIEN SE PRESENTAN METODOS PARA TRATAR EL SIDA Y METODOS PARA EVITAR O TRATAR INFECCIONES POR HIV.
ES93306114T 1992-08-07 1993-08-03 Benzoxazinonas como inhibidores de la transcriptasa inversa de vih. Expired - Lifetime ES2151897T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92660792A 1992-08-07 1992-08-07
US5480593A 1993-04-27 1993-04-27

Publications (1)

Publication Number Publication Date
ES2151897T3 true ES2151897T3 (es) 2001-01-16

Family

ID=26733517

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93306114T Expired - Lifetime ES2151897T3 (es) 1992-08-07 1993-08-03 Benzoxazinonas como inhibidores de la transcriptasa inversa de vih.

Country Status (36)

Country Link
EP (1) EP0582455B1 (es)
JP (1) JPH0780860B2 (es)
KR (1) KR100272387B1 (es)
CN (3) CN1318031C (es)
AT (1) ATE197295T1 (es)
AU (1) AU670300B2 (es)
BG (1) BG62612B1 (es)
CA (1) CA2101572C (es)
CZ (1) CZ290447B6 (es)
DE (4) DE122008000034I1 (es)
DK (1) DK0582455T3 (es)
DZ (1) DZ1707A1 (es)
ES (1) ES2151897T3 (es)
FI (2) FI115457B (es)
GR (1) GR3034754T3 (es)
HR (1) HRP931102B1 (es)
HU (1) HU223076B1 (es)
IL (1) IL106507A (es)
LU (2) LU90709I2 (es)
LV (1) LV12719B (es)
MX (1) MX192812B (es)
MY (1) MY109834A (es)
NL (2) NL300032I2 (es)
NO (3) NO304886B1 (es)
NZ (1) NZ255216A (es)
PL (2) PL176679B1 (es)
PT (1) PT582455E (es)
RO (1) RO113641B1 (es)
RU (1) RU2186775C2 (es)
SG (1) SG52698A1 (es)
SI (1) SI9300419B (es)
SK (1) SK282276B6 (es)
TW (2) TW382014B (es)
UA (1) UA42699C2 (es)
WO (1) WO1994003440A1 (es)
YU (1) YU49439B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633405A (en) * 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
US6147210A (en) 1996-07-26 2000-11-14 Dupont Pharmaceuticals Company Practical synthesis of benzoxazinones useful as HIV reverse transcriptase inhibitors
AU3736197A (en) * 1996-07-26 1998-02-20 Du Pont Pharmaceuticals Company A practical synthesis of benzoxazinones useful as hiv reverse transcripta se inhibitors
ZA9711256B (en) 1996-12-16 1999-06-15 Du Pont Merck Pharma Asymmetric synthesis of benzoxazinones
US5932726A (en) * 1996-12-16 1999-08-03 Dupont Pharmaceuticals Company Asymmetric synthesis of benzoxazinones
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
DE69841972D1 (de) * 1997-02-05 2010-12-09 Merck Sharp & Dohme Verfahren zur kristallisation eines reverstranskriptase-inhibitors, bei welchem ein anti-lösungsmittel benutzt wird
CA2285000A1 (en) * 1997-04-07 1998-10-15 Dupont Pharmaceuticals Company Asymmetric synthesis of benzoxazinones via new intermediates
US6124302A (en) * 1997-04-09 2000-09-26 Dupont Pharmaceuticals 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors
PL338894A1 (en) * 1997-09-03 2000-11-20 Merck & Co Inc Method of increasing optical purity of 2r-[1-hydroxy-1-trifluoromethy-3-cyclopropylopropin-2-yl]-4-chloroaniline
US5952528A (en) * 1997-09-03 1999-09-14 Merck & Co., Inc. Process for enhancing the optical purity
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
HRP990182A2 (en) * 1998-06-11 2000-02-29 Du Pont Pharm Co Crystalline efavirenz
US6673372B1 (en) 1998-06-11 2004-01-06 Bristol-Myers Squibb Pharma Company Crystalline Efavirenz
WO2000000475A1 (en) * 1998-06-30 2000-01-06 Du Pont Pharmaceuticals Company Substituted quinolin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US6946469B2 (en) 2001-03-28 2005-09-20 Bristol-Myers Squibb Pharma Company Cyanamide, alkoxyamino, and urea derivatives of 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones as HIV reverse transcriptase inhibitors
WO2004085406A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
AR048650A1 (es) * 2004-05-04 2006-05-10 Tibotec Pharm Ltd Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
AR056652A1 (es) * 2005-04-11 2007-10-17 Tibotec Pharm Ltd Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
WO2009044788A1 (ja) * 2007-10-05 2009-04-09 Banyu Pharmaceutical Co., Ltd. ベンゾオキサジノン誘導体
GB0720503D0 (en) 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
WO2011000532A2 (de) 2009-07-03 2011-01-06 Archimica Gmbh Verfahren zur enantioselektiven addition von organometallischen kohlenstoffnukleophilen an trifluormethylketone und verwendung des verfahrens in der synthese von hiv reverse transcriptase inhibitoren
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
EP2471783A1 (en) 2010-12-23 2012-07-04 Esteve Química, S.A. Novel polymorphic form of efavirenz
CN103664816B (zh) * 2011-01-06 2016-03-02 中国科学院上海有机化学研究所 Hiv逆转录酶抑制剂依法韦伦类化合物的一锅法不对称合成工艺
CN102675125B (zh) * 2011-03-15 2015-02-18 中国科学院上海有机化学研究所 一种4-氯-2-三氟乙酰基苯胺及其类似物的简便高效合成方法
JP7071036B2 (ja) 2019-02-15 2022-05-18 福建永晶科技股▲ふん▼有限公司 Ｆｒｉｅｄｅｌ－Ｃｒａｆｔｓ反応の新しい新方法及び当該方法に用いられる触媒
CN110372625B (zh) * 2019-08-06 2022-11-01 常州大学 蓝光照射制备4-烷甲基-4-芳基-1,3-苯并噁嗪-2(4h)-酮的方法
CN113106473B (zh) * 2021-04-14 2022-02-18 南京工业大学 一种通过连续电化学微反应器装置制备1,3-苯并噁嗪衍生物的方法
EP4416134A4 (en) * 2021-10-15 2025-09-10 Merck Sharp & Dohme Llc BENZOXAZINONE DERIVATIVES USED AS SELECTIVE CYTOTOXIC AGENTS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3526621A (en) * 1966-08-03 1970-09-01 Farmaceutical Italia Soc Substituted 3,1-benzoxazin-2-one
US3562621A (en) * 1967-07-26 1971-02-09 Technipower Inc Inrush current limiting circuit for rectifier circuits with capacitive load
DE3217012A1 (de) * 1982-05-06 1983-11-10 Dr. Karl Thomae Gmbh, 7950 Biberach Benzoxazin-2-one, deren herstellung und diese verbindungen enthaltende arzneimittel
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
IL99843A0 (en) * 1990-11-01 1992-08-18 Merck & Co Inc Synergistic combination of hiv reverse transcriptase inhibitors

Also Published As

Publication number Publication date
HRP931102A2 (en) 1997-10-31
LU90709I2 (fr) 2002-02-04
SI9300419A (en) 1994-06-30
SG52698A1 (en) 1998-09-28
NZ255216A (en) 1996-05-28
BG62612B1 (bg) 2000-03-31
TW382014B (en) 2000-02-11
DK0582455T3 (da) 2000-11-27
SI9300419B (sl) 2002-10-31
EP0582455A1 (en) 1994-02-09
NO2008008I1 (no) 2008-06-30
EP0582455B1 (en) 2000-11-02
CN1221608A (zh) 1999-07-07
CN1107505C (zh) 2003-05-07
AU670300B2 (en) 1996-07-11
PT582455E (pt) 2001-03-30
NO950424L (no) 1995-04-06
CA2101572A1 (en) 1994-02-08
CN1318031C (zh) 2007-05-30
FI115457B (fi) 2005-05-13
ATE197295T1 (de) 2000-11-15
DE122008000034I1 (de) 2008-10-02
NL300347I1 (nl) 2008-07-01
KR950702970A (ko) 1995-08-23
CN1090277A (zh) 1994-08-03
NL300032I2 (nl) 2001-04-02
FI20040309A7 (fi) 2004-02-27
JPH0780860B2 (ja) 1995-08-30
MY109834A (en) 1997-08-30
WO1994003440A1 (en) 1994-02-17
DZ1707A1 (fr) 2002-02-17
YU49439B (sh) 2006-03-03
UA42699C2 (uk) 2001-11-15
LV12719B (lv) 2001-12-20
LU91446I2 (fr) 2008-07-28
NO950424D0 (no) 1995-02-06
FI950508A0 (fi) 1995-02-06
KR100272387B1 (ko) 2000-11-15
RU95107403A (ru) 1996-11-20
JPH06184124A (ja) 1994-07-05
MX9304775A (es) 1994-05-31
AU4449693A (en) 1994-02-10
RO113641B1 (ro) 1998-09-30
HRP931102B1 (en) 2001-06-30
BG99383A (bg) 1995-09-29
LV12719A (lv) 2001-09-20
MX192812B (es) 1999-07-30
IL106507A (en) 1997-11-20
HUT71219A (en) 1995-11-28
CA2101572C (en) 2001-08-28
TWI233436B (en) 2005-06-01
RU2186775C2 (ru) 2002-08-10
FI950508L (fi) 1995-02-06
CN1250652A (zh) 2000-04-19
SK16195A3 (en) 1995-07-11
NO304886B1 (no) 1999-03-01
CZ28695A3 (en) 1995-09-13
NO2000004I1 (no) 2000-06-16
DE69329608D1 (de) 2000-12-07
YU53093A (sh) 1996-10-09
IL106507A0 (en) 1993-11-15
DE10199013I1 (de) 2001-05-23
SK282276B6 (sk) 2002-01-07
CZ290447B6 (cs) 2002-07-17
HU223076B1 (hu) 2004-03-01
NL300032I1 (es) 2001-02-01
GR3034754T3 (en) 2001-02-28
PL176679B1 (pl) 1999-07-30
DE10199013I2 (de) 2007-05-24
HK1009267A1 (en) 1999-05-28
PL307348A1 (en) 1995-05-15
CN1051767C (zh) 2000-04-26
PL175615B1 (pl) 1999-01-29
DE69329608T2 (de) 2001-05-03
HU9500366D0 (en) 1995-03-28

Similar Documents

Publication Publication Date Title
ES2125251T3 (es) Inhibidores de la proteasa del vih.
MX9304775A (es) Benzoxazinonas como inhibidores de hiv transcriptasa inversa.
ES2177868T3 (es) Hidroxietilaminosulfonamidas de alfa- y beta-aminoacidos utiles como inhibidores de proteasas retroviricas.
MX9403380A (es) Inhibidores de proteasa de vih utiles para el tratamiento de sida.
ES2174921T3 (es) Inhibidores de la proteasa del vih.
ES2182837T3 (es) Piran-2-onas y 5,6-dihidropiran-2-onas utiles en el tratamiento del sida y de otros retrovirus.
ES2150933T3 (es) Inhibidores de la proteasa vih utiles para el tratamiento del sida.
MX9204720A (es) Derivados de quinazolina como inhibidores de transcriptasa inversa de vih.
ES2186787T3 (es) Utilizacion de ritonavir (abt-538) para mejorar la farmacocinetica de medicamentos metabolizados por el citocromo p450 en un metodo de tratamiento del sida.
ES2181725T3 (es) Inhibidores de hiv proteasa.
MX9304359A (es) Derivados de rapamicina.
UY26380A1 (es) Inhibidores de fab i
ES2186811T3 (es) Derivados de feniltiazol con propiedades anti-virus herpes.
ES2157252T3 (es) Aplicacion del riluzol en el tratamiento del neuro-sida.
ES2178036T3 (es) Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que le contienen.
ES2101252T3 (es) Inhibidores de la proteasa del hiv utiles para el tratamiento del sida.
MX9304361A (es) Derivados de rapamicina.
UY25780A1 (es) Nuevos antibióticos macrólidos
AR003176A1 (es) Una composicion farmaceutica para inhibir el crecimiento de cancer
MX9308010A (es) Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
MX9302681A (es) Nuevas quinazolinas como inhibidores de transcriptasa inversa hiv.
CO4130200A1 (es) Inhibidores de proteasa del hiv utiles en el tratamiento del sida
MX9705916A (es) Terapia de combinacion para infeccion por vih usando el inhibidor de proteasa de vih indinavir y el inhibidor de transcriptasa inversa 3tc, opcionalmente junto con azt, ddi, o ddc.
ES2096874T3 (es) Inhibidor de la proteasa de hiv util para el tratamiento del sida.
MX9301863A (es) Morfolin y tiomorfolin 4-ilamidas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 582455

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: EFAVIRENZ (STOCRIN).

Spc suppl protection certif: C200100006

Filing date: 20010101

Free format text: EFAVIRENZ (STOCRIN)

Spc suppl protection certif: C200100006

Filing date: 20010101

SPCG Supplementary protection certificate granted

Free format text: EFAVIRENZ (STOCRIN, SUSTIVA)

Spc suppl protection certif: C200100006

Filing date: 20010123

Expiry date: 20140528

Effective date: 20031222